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Abstract
Background: Mutations within the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial and sporadic
Parkinson’s disease. The multidomain protein LRRK2 exhibits overall low GTPase and kinase activity in vitro.
Methodology/Principal Findings: Here, we show that the rho guanine nucleotide exchange factor ARHGEF7 and the small
GTPase CDC42 are interacting with LRRK2 in vitro and in vivo. GTPase activity of full-length LRRK2 increases in the presence
of recombinant ARHGEF7. Interestingly, LRRK2 phosphorylates ARHGEF7 in vitro at previously unknown phosphorylation
sites. We provide evidence that ARHGEF7 might act as a guanine nucleotide exchange factor for LRRK2 and that R1441C
mutant LRRK2 with reduced GTP hydrolysis activity also shows reduced binding to ARHGEF7.
Conclusions/Significance: Downstream effects of phosphorylation of ARHGEF7 through LRRK2 could be (i) a feedback
control mechanism for LRRK2 activity as well as (ii) an impact of LRRK2 on actin cytoskeleton regulation. A newly identified
familial mutation N1437S, localized within the GTPase domain of LRRK2, further underlines the importance of the GTPase
domain of LRRK2 in Parkinson’s disease pathogenesis.
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Introduction
The multidomain protein kinase LRRK2 is an attractive
therapeutic target as it was shown that this previously unknown
kinasecancauseParkinson’sdisease(PD)ifmutated[1,2].Mutations
within LRRK2 contribute to 5-6% of all cases of autosomal-
dominant as well as to 1-2% of cases of sporadic Parkinson’s disease.
Pathogenic mutations are primarily found in the enzymatic domains
of LRRK2, the GTPase and the kinase domain. The pathogenic
mechanism and the normal function of the protein LRRK2 are far
from being understood [3,4,5,6]. West et al. were the first to show
that mutated LRRK2 exhibits increased kinase activity in vitro [7].
This important finding led to numerous investigations on how
LRRK2 kinase activity might be regulated. Current evidence sug-
gests dimerization [8,9,10,11], autophosphorylation [7,8,9,12,13,14,
15,16,17,18,19] and intramolecular signaling through the GTPase
domain of LRRK2 itself [10,13,20,21,22,23]. Since activity of
LRRK2 in vitro is rather small compared to known GTPases and
kinases the question remains if normal LRRK2 primarily acts
through its enzymatic activities or rather serves as a scaffold protein
regulating cellular processes by orchestrating protein complexes.
The discovery of endogenous interactors of LRRK2 was greatly
limited through the lack of specific antibodies. We previously used
siRNA knockdown in SH-SY5Y to gain further insight into
pathways regulated by LRRK2 [24]. Interestingly, we found a de-
regulation of actin-cytoskeleton signaling cascades with the guanine
nucleotide exchange factor ARHGEF7 and the small GTPase
CDC42 being the most significantly up-regulated genes. Several
lines of evidence suggest an involvement of LRRK2 in regulation of
neurite outgrowth [25,26]. We therefore characterized these central
regulators of the cytoskeleton as potential interactors of LRRK2.
Results
ARHGEF7 and CDC42 interact and partially co-localize
with LRRK2
First, we generated V5-tagged ARHGEF7 and CDC42 and
tested these proteins for interaction with co-expressed full-length
myc-tagged LRRK2 in HEK293 cells. A robust interaction of
LRRK2 with both proteins was demonstrated (Figure 1). Over-
expressed LRRK2 also interacts with ARHGEF7 and CDC42 in
SH-5YSY cells (data not shown).
Next, we investigated if endogenous LRRK2 (detected with the
Novus 267 LRRK2 antibody) co-localizes with endogenous
ARHGEF7, CDC42 and ACTB in SH-SY5Y. Partial co-
localisation of all three proteins is shown in retinoic acid
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13762differentiated SH-SY5Y cell bodies and neurites supporting a
potential in vivo relevance of these interactions, respectively
(Figure 2). Specificity of the antibodies was demonstrated by
immunoblotting (Figure 2 and Figure S1).
The endogenous interaction of LRRK2 with ARHGEF7 and
CDC42 in mouse brain lysates could robustly be demonstrated by
co-immunoprecipitation using a monoclonal anti-LRRK2 antibody
described by Bauer and colleagues ([27], Figure 3). Figure S2A
shows that the guanine nucleotide exchange factor SOS1 did not
interact with LRRK2. As positive control we confirm the already
known interaction between LRRK2 and c-tubulin (TUBA,
[28,29,30]), here also shown in mouse brain lysate (Figure S2B).
Reduced interaction between ARHGEF7 and R1441C
LRRK2 mutant in HEK293 cells
Next, we analyzed if the known pathogenic mutations R1441C
and G2019S affect the interaction between ARHGEF7 and
LRRK2. As controls a GTPase-impaired version (T1348N) and a
kinase-dead version (K1906M) of LRRK2 were used, respectively.
As shown in Figure 4A (lane 2, 3 and 4) there is no difference
between WT and G2019S and kinase-dead LRRK2 interacting
with ARHGEF7 pulldowned with V5-agarose beads. Clearly, the
R1441C mutation in LRRK2 leads to a reduced binding between
R1441C mutant LRRK2 and ARHGEF7 (lane 5 compared to
lane 2). This result was confirmed with an inverse co-immuno-
precipitation using myc-agarose beads coupling LRRK2 and
pulling down ARHGEF7 (Figure 4B). Although expression levels
of the potentially instable T1348N mutant (Figure 4A, lane 6) are
less compared to other mutants, interaction still takes place. The
quantification is shown in Figure S3.
ARHGEF7 enhances GTP binding of R1441C-LRRK2
It has been previously shown that LRRK2 without guanine
nucleotide exchange factors (GEFs) or GTPase-activating proteins
(GAPs) preferentially binds to GTP versus GDP [12,23,31]. We
therefore examined if ARHGEF7 can influence the affinity of
LRRK2 to GTP-sepharose. Co-expression of ARHGEF7 with
WT LRRK2 leads to an induction of LRRK2 protein expression
(Figure 5, lane 2 compared to lane 1); a finding that is consistent
with increased GTP binding of LRRK2. We then tested the
G2019S (Figure 5, lane 3 and 4) and K1906M (Figure 5, lane 5
and 6) mutation and did not detect any influence of LRRK2 GTP
binding when co-expressing ARHGEF7. As shown by others the
T1348N mutation albeit with low expression levels, is not able to
bind GTP (Figure 5, lane 9/10). Interestingly, the R1441C
mutation if co-expressed with ARHGEF7 leads to a significant
two-fold increase in GTP binding affinity to LRRK2 (Figure 5,
lane 8 compared to lane 7). The quantification is shown in
Figure S4.
ARHGEF7 acts as a guanine nucleotide exchange factor
of LRRK2 in HEK293 cells
To further analyse the functional impact of the ARHGEF7 -
LRRK2 interaction we tested if a GEF-dead variant of
ARHGEF7 [32] is still able to bind LRRK2. In Figure 6A we
show that the guanidine nucleotide exchange activity of
ARHGEF7 is not relevant for binding to LRRK2 in general.
Other groups previously demonstrated that 2 mM GTP is able to
reduce the binding of LRRK2 to GTP-sepharose beads [12,31].
We performed a competition assay using four different concen-
trations of soluble GTP with 0 mM GTP as baseline. We
estimated the strength of LRRK2 binding to GTP mediated by
ARHGEF7 indicated by fewer amounts of GTP to compete with
GTP-sepharose for the binding to LRRK2. As expected co-
expression of full-length myc-tagged LRRK2 and empty V5
vector leads to reduced binding of LRRK2 to GTP-sepharose
with increasing amounts of soluble GTP (Figure 6B). Co-
expression of full-length myc-tagged LRRK2 with wild-type
Figure 1. Co-immunoprecipitation of full-length LRRK2 with ARHGEF7 (A) and CDC42 (B). Myc-tagged full-length LRRK2 and the
indicated V5-tagged constructs (A: ARHGEF7, B: CDC42) were co-transfected in HEK293 cells and analyzed in V5-Co-immunoprecipitation (V5-IP).
60 mg of protein lysate were used as input control. Immunoblotting was performed using V5 and myc antibodies. Empty V5 vector was used as
negative control for each condition.
doi:10.1371/journal.pone.0013762.g001
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beads at already much lower concentrations of soluble GTP.
Compared to conditions without expressing ARHGEF7 there is a
significant difference in bound LRRK2 on GTP-sepharose beads
at 1 mM and 2 mM soluble GTP respectively (Figure 6C). Co-
expression of full-length myc-tagged LRRK2 with a GEF-dead
variant of ARHGEF7 does not enhance GTP exchange of GTP-
bound LRRK2. With this qualitative analysis we conclude that
ARHGEF7 has the potential to act as a guanine nucleotide
exchange factor for LRRK2.
GTPase activity of full-length LRRK2 is increased in the
presence of recombinant ARHGEF7 in vitro
We further investigated the influence of recombinant ARH-
GEF7 on the GTPase activity of recombinant full-length LRRK2
using a quantitative GTP hydrolysis assay previously described
[30]. In our hands, GTP hydrolysis activity of LRRK2 in the
presence of bovine serum albumin as negative control is 18%
(62.2) (Figure 7, 15 min lane 2) and can be induced with
ARHGEF7 to 36.8% (64.7) (Figure 7, 0 min lane 1, 15 min lane
3). In comparison, GTP hydrolysis activity of ARHGEF7 alone is
4.9% (60.2) (Figure 7, 15 min lane 4). The GTP hydrolysis assay
points towards an ARHGEF7-mediated, significant twofold
induction of LRRK2 GTPase activity. Both the GTP hydrolysis
assay and the GTP exchange assay support the notion that
ARHGEF7 might be the first identified GEF for LRRK2.
LRRK2 phosphorylates ARHGEF7 in vitro
Since LRRK2 interacts with ARHGEF7 we investigated if
ARHGEF7 is also a substrate of LRRK2. In order to address this
question we performed an in vitro kinase assay [9] by incubation of
purified wild-type LRRK2 with ARHGEF7, which has been
recombinantly expressed as MBP-fusion protein in E. coli. The
kinase-dead variant K1906M served as negative control to confirm
specificity of the observed signals. The Tag-only negative control
shows no signal as previously published by Gloeckner et al. 2009
[9]. As shown in Figure 8A, wild-type LRRK2 phosphorylates
ARHGEF7. In order to identify the exact location of LRRK2
phosphorylated residues within ARHGEF7 we conducted a
mapping approach by mass spectrometry. Two threonine residues,
T107 and T143, within the ARHGEF7 N-terminus were
identified with high confidence. The spectra of the corresponding
tryptic peptides are shown in Figure 8B. The phosphorylation site
at T143 was additionally confirmed by a peptide gained from
chymotryptic proteolysis (data not shown). The identified LRRK2
phosphorylation sites are located between the calponin homology
(CH) and the SH3 domain of ARHGEF7 (Figure 8C).
N1437S is a potentially new pathogenic mutation within
LRRK2
Within a small family with autosomal dominant Parkinson’s
disease (Figure S5) we identified the new potentially pathogenic
mutation N1437S segregating with the disease. The N1437 residue
Figure 2. Co-localisation of LRRK2 with ARHGEF7, CDC42 and ACTB in differentiated SH-SY5Y cells. Differentiated SH-SY5Y cells were double
stained for endogenous LRRK2-CY2 and ARHGEF7-CY3, ACTB-CY3 or CDC42-CY3 and analyzed with confocal microscopy (LSM510, Zeiss). Specificity of the
antibodies is indicated by immunoblotting. The specificity of the Novus 267 LRRK2 antibody is shown by means of RNAi (Figure S1). Scale bar =10 mm.
doi:10.1371/journal.pone.0013762.g002
ARHGEF7 Acts as GEF for LRRK2
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13762Figure 3. Interaction analysis of ARHGEF7, CDC42 and LRRK2 from mouse brain lysates. Lysate of whole mouse brain was used for
pulldown of endogenous LRRK2 on ProteinG agarose beads. Immunoblotting with specific antibodies for endogenous proteins indicates the
enrichment of LRRK2 on the beads as well as the coupling of the interacting proteins ARHGEF7 (A) and CDC42 (B). Coupling of IgG on ProteinG
agarose beads and incubating with the same lysate was used as negative control.
doi:10.1371/journal.pone.0013762.g003
Figure 4. Co-immunoprecipitation of ARHGEF7 with mutated LRRK2. (A) Myc-tagged full-length LRRK2 with different mutations (WT,
G2019S, K1906M, R1441C, T1348N) was co-transfected with V5-tagged ARHGEF7 in HEK293 cells and subjected to V5-Co-immunoprecipitation.
Transfection with empty V5 vector was used as negative control (lane 1). 60 mg of protein lysates were used as input control. Immunoblotting was
performed using antibodies against V5 and myc. Interaction strength between ARHGEF7 and mutated LRRK2 (lane 3–6) was compared to WT LRRK2
(lane 2). (B) Confirmation of reduced binding between ARHGEF7 and full-length R1441C LRRK2 in comparison to full-length WT LRRK2 using myc-IP.
doi:10.1371/journal.pone.0013762.g004
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hotspot and was not found in 1000 control chromosomes. The
recent finding of the N1437H variant as being pathogenic from
Aasly et al. 2010 [33] underlines the central importance of the
GTPase domain for the function and the disease pathogenesis of
LRRK2 associated disease.
Using a LRRK2 fragment containing the Roc, COR and kinase
domains (Roc-COR-PK) we first analyzed the interaction of wild-
type and mutant LRRK2 Roc-COR-PK (R1441C, N1437S and
T1348N) with wild-type ARHGEF7 in HEK293 cells. As can be
seen in Figure 9A there is a decreased interaction of over-
expressed mutant LRRK2 with ARHGEF7. The reduced
interaction is even more profound using full-length N1437S
mutant LRRK2 (Figure 9B) and comparable to the reduced
interaction between full-length R1441C-LRRK2 and ARHGEF7.
Over-expression of full-length R1441C-LRRK2 with ARH-
GEF7 leads to a significant two-fold increase in GTP binding
affinity of R1441C-LRRK2 (Figure 5). This can not be observed
with the N1437S Roc-COR-PK fragment (Figure 9C) and not
with full-length N1437S LRRK2 (Figure 9D) pointing towards
different mechanisms exhibited by the two different LRRK2
mutations R1441C and N1437S, respectively.
Discussion
Even years after the initial description of LRRK2 mutations as a
frequent cause of familial Parkinson’s disease, only little is known on
the normal function of this multidomain protein GTPaseand kinase.
Since LRRK2-associated disease closely mimics sporadic idiopathic
Parkinson’s disease with respect to clinical findings, progression, and
pathology, there is particular interest in understanding the
mechanisms underlying LRRK2 and its pathogenic variants.
After successful cloning and expression of the protein in cell
lines, GTPase as well as kinase activity could be demonstrated in
vitro [7,8,12,20,34,35,36]. Several potential substrates have been
described, most convincingly LRRK2 as being its own substrate
subjected to autophosphorylation [8,11,15]. Recently, phosphor-
ylation sites have been identified in the GTPase domain
[14,15,17]. This is an important finding and the functional
relevance with potential impact on dimerization, GTPase and
kinase activity is eagerly awaited.
There is evidence from different studies demonstrating that
LRRK2 might influence and regulate neurite outgrowth [25,26];
however, the underlying mechanisms are yet unknown. Abeliovich
and colleagues observed increased neurite outgrowth, a process
which is dependent on cytoskeletal dynamics, after viral shRNA
knockdown of LRRK2 [26]. Here we propose a mechanism by
whichLRRK2might execute itsinfluenceon the actin cytoskeleton.
The cytoskeleton plays an important role in maintenance of
shape, building protrusions and movement of the cell in general.
Central regulators of the cytoskeleton are small GTPases namely,
CDC42, Rho and Rac. In order to become activated, GTPases
require guanine nucleotide exchange factors (GEFs) that allow
switching between GDP and GTP bound states. Of interest, CDC42
is activated by the guanine nucleotide exchange factor ARHGEF7
[37], leading to polymerization of actin and inducing protrusion of
the cell membrane. Both genes, CDC42 and ARHGEF7, are
significantly up-regulated after acute LRRK2 knockdown by siRNA
Figure 5. LRRK2-GTP-binding influence through ARHGEF7. GTP-binding efficiency of full-length myc-tagged LRRK2 (WT, G2019S, K1906M,
R1441C, T1348N) on GTP-sepharose was analysed in comparison between co-expression of empty V5 vector or V5-tagged ARHGEF7. Immunoblotting
was performed with V5 and myc antibodies. Differences were analysed by pixel densitometry and were indicated. Errors are SEM. *p-value #0.05.
doi:10.1371/journal.pone.0013762.g005
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increase in neurite outgrowth after acute knockdown in rat embryos
observed by MacLeod and colleagues. To underline the possible link
between LRRK2 and both ARHGEF7 and CDC42, we decided to
perform co-immunoprecipitation experiments. LRRK2 interacts
with ARHGEF7 and CDC42, as can robustlybeshown invitroincell
lines and in vivo in mouse brain lysates. Evidence for a functional
relevance of this interaction is provided by partial co-localization in
SH-SY5Y cells.
Several questions became apparent. We first asked if ARH-
GEF7 might act as a guanine nucleotide exchange factor for the
role of LRRK2 as GTPase. To address this question step by step
we compared binding of LRRK2 mutants with ARHGEF7 in vitro.
Over-expression of wild-type and mutant LRRK2 (R1441C,
N1437S, G2019S, T1348N and K1906M) in HEK293 cells points
towards a reduced binding of R1441C and N1437S mutant
LRRK2 with ARHGEF7. The interaction between ARHGEF7
and kinase impaired mutants remains unchanged. This might
indicate that the interaction depends on the GDP bound state of
LRRK2. The R1441C variant exhibits a reduced GTP hydrolysis
activity [20,36] and should therefore preferably remain in a GTP
bound state. ARHGEF7 acts as GEF and is able to convert a GDP
bound protein to the GTP bound state, resulting in a preferred
binding to GDP bound proteins. In the R1441C LRRK2
condition less GDP bound LRRK2 will be available leading to a
reduced binding signal to ARHGEF7. Next, we investigated if co-
expression of LRRK2 and ARHGEF7 leads to an increase of the
affinity of LRRK2 towards GTP. Only with the R1441C mutant
an increased affinity of LRRK2 towards GTP could be
demonstrated. This finding additionally points to ARHGEF7 acts
as GEF for LRRK2. All of the available GDP bound R1441C
LRRK2 proteins will be converted to the GTP bound state, will
Figure 6. Interaction of GEF-dead ARHGEF7 with LRRK2 (A) and Influence of ARHGEF7 on GTP exchange capacity of LRRK2 (B). (A/B)
Co-expression of full-length myc-tagged LRRK2 and either ARHGEF7-WT-V5 or ARHGEF7-GEF-dead-V5 or empty V5 vector as negative control in
HEK293 cells and subsequent analysis of interaction strength with V5-Co-immunoprecipitation. 60 mg of protein lysates were used as input control.
Immunoblotting was performed using myc or V5 antibodies. (B/C) Same transfections as in (A) were used for GTP exchange analysis on GTP-
sepharose (GTP-IP) with competition of 0 (as baseline), 0.5, 1, 2, 4 mM soluble GTP. Detection with myc antibody is used to analyse the bound full-
length LRRK2 on GTP-sepharose beads (B). Quantification of pixel densities was performed of three independent experiments. A nonspecific band
was used as loading control. (C). Error bars = SEM, *p-value #0.05.
doi:10.1371/journal.pone.0013762.g006
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solution as efficiently as in the WT condition. Therefore the
enhanced GTP binding of R1441C LRRK2 under influence of
ARHGEF7 occurs. Then, we applied a competition assay to
analyse the dynamic impact of the ARHGEF7 - LRRK2
interaction. A GEF-dead variant of ARHGEF7 that is still able
to bind LRRK2, serves as control. As was expected, co-expression
of full-length myc-tagged LRRK2 and empty V5 vector leads to
reduced binding of LRRK2 to GTP-sepharose with increasing
amounts of soluble GTP. However, co-expression of full-length
myc-tagged LRRK2 with wild-type ARHGEF7 leads to reduced
LRRK2 binding on GTP-sepharose beads at already much lower
concentrations of soluble GTP whereas co-expression of full-length
myc-tagged LRRK2 with a GEF-dead variant of ARHGEF7 does
not enhance GTP exchange of GTP bound LRRK2. The GTP
hydrolysis assay points to a twofold increase of LRRK2 GTPase
activity in the presence of ARHGEF7. We therefore conclude that
at least in vitro ARHGEF7 act as the first identified LRRK2-GEF.
Since LRRK2 interacts with ARHGEF7 and ARHGEF7 is known
to be phosphorylated on several sites we also asked if ARHGEF7
might be a substrate of the kinase LRRK2. In order to address this
question an in vitro kinase assay was performed and the phosphory-
lation sites were mapped by tandem mass spectrometry. Most
interestingly LRRK2 phosphorylates ARHGEF7 at positions previ-
ously unknown as being targets for phosphorylation: T107 and T143.
Although this adds another layerofcomplexity and awaitsfurther
validation in vivo, we propose the following model (Figure 10):
ARHGEF7 serves as a guanine nucleotide exchange factor for
LRRK2 through mediating the exchange of a GDP to a GTP
bound state and by this activating LRRK2. Active LRRK2 is
present as autophosphorylated dimer and in this conformation is
capable of phosphorylating potential substrates. One substrate is
ARHGEF7. ARHGEF7 acts then as a feedback control on LRRK2
activity but also functions on other target proteins like CDC42.
The discovery of pathways in which LRRK2 is involved will
hopefully lead to a better understanding of the pathomechanisms
of familial and sporadic forms of Parkinson’s disease. The
identification of crucial proteins within these pathways, positions
these proteins as targets for new therapeutical strategies.
Materials and Methods
Plasmid Constructs
Full-length human LRRK2 construct was amplified from the
pcMV_XL4_Park8 Vector (Origine, Rockville, USA) and cloned
in a pcDNA
TM3.1/myc-His vector (Invitrogen). The G2019S,
K1906M, R1441C, N1437S and T1348N mutation were
introduced by site-directed mutagenesis (QuikChange
TM XL
Site-Directed Mutagenesis Kit, Stratagene, La Jolla, USA). Roc-
COR-PK (WT, R1441C, N1437S and T1348N) constructs
(aa1330-2147) were amplified from the corresponding full-length
LRRK2 Vector and introduced in pcDNATM3.1/myc-His vector
(Invitrogen) by usage of BamHI and XhoI. HEK293 cDNA
(prepared in our lab) was used for amplification and cloning of
ARHGEF7 (ENSG00000102606/ENST000000317133) and
CDC42 (ENSG00000070831/ENST00000315554) constructs in
pCMV-vector thereby introducing a V5-tag at the C-terminus.
Generation of the GEF-dead variant (L386R/L387S) of the
ARHGEF7 construct [32] was performed by a two step site-
directed mutagenesis by using the oligonucleotide GATAAATACCC-
TACGCGGCTCAAAGAGCTCGAGA to introduce the L386R and
thereafter the oligonucleotide GATAAATACCCTACGCGGTCCAAA-
GAGCTCGAGAGACA to introduce the L387S mutation. For in vitro
kinase assays LRRK2 variants were subcloned into the N-SF-TAP
vector [38]. For the generation of maltose-binding protein MBP
fusion protein, full-length ARHGEF7 was subcloned into the
pMAL Vector [16]. For in vitro LRRK2 GTPase assays, ARHGEF7
was subcloned into the SF-TAP vector, allowing efficient purifica-
tion of full length ARHGEF7 from HEK293T cells.
Antibodies and other reagents
The following antibodies were used in these studies: mouse
monoclonal anti-c-Myc (#sc-40, WB=1:200, Santa Cruz Biotech-
nology),anti-V5rabbitpolyclonalantibody(#V8137,WB=1:5000,
Sigma-Aldrich), anti-LRRK2 rabbit polyclonal antibody (#NB300-
267, WB=1:1000, IF=1:200, Novus Biologicals), rat monoclonal
anti-LRRK2 antibody [27], mouse polyclonal ARHGEF7 antibody
(#H00008874-A01, WB=1:1000, IF=1:100 Novus Biologicals),
mouse monoclonal CDC42 antibody [M152] (#ab41429,
WB=1:500, IF=1:100, Abcam) and anti-b-Actin mouse monoclo-
nal antibody (Clone AC15, WB=1:10,000, IF=1:5000, Sigma-
Aldrich). Myc-agarose beads (A 7470) and V5-agarose beads (A
7345) for immunoprecipitation studies were purchased from Sigma-
Aldrich. Gamma-aminohexyl-GTP-sepharose (Jena Biosciences)
was used for GTP binding and GTP competition assays.
Cell transfection
HEK293 cells (ACC 305) and SH-SY5Y cells (ACC 209) were
purchased from DSMZ. HEK293 cells were maintained in D-
MEM (+4500 mg/l Glucose, +GlutaMAX
TM, -Pyruvat, Gibco)
and 10% FCS (Gibco) and 1% penicillin/streptomycin (Gibco).
Figure 7. ARHGEF7 augments GTPase activity of full-length
LRRK2. Hydrolysis of [a-
33P]GTP was assessed in the presence of: (lane
1 and lane 3) LRRK2 and ARHGEF7 (0 min and 15 min, respectively),
(lane 2) LRRK2 and bovine serum albumin (15 min), and (lane 4)
ARHGEF7 alone (15 min).
doi:10.1371/journal.pone.0013762.g007
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15% FCS. HEK293 cells were transiently transfected by using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. RNA Interference of LRRK2 in SH-SY5Y cells was
performed as previously described [24].
Immunoprecipitation and immunoblotting
Protein lysis for immunoprecipitation studies were performed
48 h after transiently transfection with 150 ml NP40-Lysisbuffer
(PBS +0,5% NP40 +0,5% deoxycholate) with freshly added
complete protease inhibitor cocktail (Roche Molecular Biochem-
icals) and phosphatase inhibitor cocktail I and II (Sigma Aldrich).
Therefore cells were incubated 30 min on ice while vortexing each
10 min following by 15 min centrifugation at 4uC at 13.000 rpm.
Protein concentration of the supernatant was analyzed by the
Bradford method. 1000 mg of protein lysate was used for
immunoprecipitation with either myc-agarose beads or V5-
agarose beads. After rotating the beads over night at 4uC, Pellet
was washed once with NP40-Lysisbuffer and three times with PBS.
Proteins bound to the agarose beads were eluted with 20 ml
Figure 8. LRRK2 phosphorylates ARHGEF7 at threonine residues within its N-terminus. (A) In vitro kinase assay by incubating either WT
(lane 1) or kinase-dead (K1906M) LRRK2 (lane 2) with ARHGEF7. Upper panel: Prior to autoradiography samples were blotted onto a PVDF membrane.
The upper bands correspond to LRRK2 autophosphorylation, the lower bands to phosphorylation of MBP-tagged ARHGEF7. Lower panel: loading
control by ponceau staining of the membrane. Fragments of the ARHGEF7 MBP-fusion protein are indicated by asterisks. A fragment corresponding
to the MBP tag only (indicated by #) is not phosphorylated demonstrating that LRRK2 specifically phosphorylates sites within ARHGEF7. (B)
Identification of phosphorylated sites within ARHGEF7 by tandem mass spectrometry. MSA-spectra corresponding to tryptic phosphopeptides are
shown indicating that ARHGEF7 phosphorylation by LRRK2 occurs at the threonine residues T107 and T143. (C) Graphical representation of the
identified phosphorylation sites between the calponin homology domain (CH) and the SH3 domain in the N-terminus of ARHGEF7.
doi:10.1371/journal.pone.0013762.g008
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lysate was loaded on SDS-PAGE. As input control 60 mg of the
protein lysate was used.
Immunoprecipitation from mouse brain
Protein lysis of whole brain of C57Bl6 WT mice was performed
using 1.5 ml PBS with 1% TritonX100 and freshly added
complete protease inhibitor cocktail (Roche Molecular Biochem-
icals) and phosphatase inhibitor cocktail I and II (Sigma Aldrich)
with a dounce -homogenisator. After 45 min incubation with
rotation at 4uC the lysate was centrifuged for 15 min at full speed.
The concentration of the supernatant was analyzed by the
Bradford method. For coupling of the endogenous proteins to
the specific LRRK2 antibody (rat monoclonal anti-LRRK2 1E11,
IP=1:200, generated by E. Kremmer, Helmholtz Zentrum
Mu ¨nchen, Munich, Germany) 3000 mg of protein lysate was
incubated in a volume of 200 ml for 3 h with rotating at 4uC. As
negative control normal rat IgG (PeproTech, 1:200) was coupled
to the beads. Thereafter 40 ml of ProteinG-agarose beads (#P4691
Sigma Aldrich) were added for another 2 h. The beads were
washed once with the lyses buffer and twice with PBS before
adding 25 ml 2xLaemmli buffer to the beads. The samples were
incubated 10 min at 70uC and loaded on SDS-PAGE. For
detection the following antibodies were used: mouse polyclonal
ARHGEF7 antibody (#H00008874-A01, WB=1:1000, Novus
Biologicals), mouse monoclonal CDC42 antibody [M152]
(#ab41429, WB=1:500, Abcam), mouse anti-SOS1 (#610095,
WB=1:250, IP=1:25, BD Transduction Laboratories), Anti-a-
Tubulin Mouse mAb (#CP06, WB=1:50000, Calbiochem) and
rat monoclonal anti-LRRK2 (1E11, WB=1:1000 [27]. We
obtained ethics approval for protein lysis of whole brain of
C57Bl6 WT mice by the ‘‘Regierungspra ¨sidium Tu ¨bingen’’.
Figure 9. Co-immunoprecipitation of LRRK2 with ARHGEF7 (A/B) and LRRK2-GTP-binding influence through ARHGEF7 (C/D). (A)
Myc-tagged Roc-COR-PK Fragment of LRRK2 with indicated GTPase influencing mutations were co-transfected with V5-tagged ARHGEF7 in HEK293
cells and analyzed in V5-Co-immunoprecipitation (V5-IP). 60 mg of protein lysate were used as input control. Immunoblotting was performed using
V5 and myc antibody. Empty V5 vector was used as negative control for each condition. Binding of Roc-COR-PK with mutations to ARHGEF7 is
indicated in relation to WT Roc-COR-PK with SEM and p-Value. (B) Myc-tagged full-length N1437S-LRRK2 was co-transfected with V5-tagged ARHGEF7
in HEK293 cells and analyzed in V5-Co-immunoprecipitation (V5-IP). 60 mg of protein lysate were used as input control. Immunoblotting was
performed using anti V5 and myc antibodies. Binding of N1437S LRRK2 to ARHGEF7 is indicated in relation to WT LRRK2 with SEM and p-Value. (C)
GTP-binding efficiency of myc-tagged Roc-COR-PK Fragment (WT, R1441C, N1437S) of LRRK2 on GTP-sepharose was analysed in comparison between
co-expression of empty V5 vector or V5-tagged ARHGEF7. Immunoblotting was performed with V5 and myc antibodies. Differences were analysed by
pixel densitometry and were indicated. Errors are SEM. *p-value #0.05. (D) GTP-binding efficiency of full-length myc-tagged N1437S LRRK2 on GTP-
sepharose was analysed in comparison between co-expression of empty V5 vector or V5-tagged ARHGEF7. Immunoblotting was performed with anti
V5 and myc antibodies. Differences were analysed by pixel densitometry and were indicated. Errors are SEM. *p-value #0.05.
doi:10.1371/journal.pone.0013762.g009
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GTP binding assay was performed as described by West et al.
except of using 150 ml lysis buffer G per 6well of 48h transiently
transfected HEK293 cells [12]. 800 mg of each lysate was
incubated for 3 h on 20 ml GTP-sepharose while rotating at
4uC. 2 mM GDP was added for another 1 h rotating. GTP-
sepharose was washed once with lysis buffer G and two times with
PBS. GTP-bound proteins were eluted with 20 ml 2xLa ¨mmli
buffer, incubated for 10 min at 70uC and completely loaded on
SDS-PAGE. As input control 60 mg of the protein lysate was used.
The amount of GTP-bound LRRK2 was normalized to input
levels.
GTP competition assay
GTP competition analysis was done as described for GTP
binding assay. 4 wells of transfected HEK293 cells were lysed and
pooled. For each competition condition (0, 0.5, 1, 2, 4 mM GTP)
300 mg of lysate was incubated for 1 h on 20 ml GTP-sepharose
beads. Afterwards the specified amount of GTP was added and the
incubation was performed for one additional hour.
GTP hydrolysis assay
GTP hydrolysis assays based on thin-layer chromatography
were performed as described in detail elsewhere [30]. Briefly,
recombinant full-length LRRK2 (50 nM) and/or ARHGEF7
(75 nM) were pre-incubated with 500 nM [a-
33P]GTP (3000Ci/
mmol) in 20 M Tris, pH 8.0, 1 mM EDTA, 2 mM dithiothreitol,
for 5 min at room temperature. The reaction was started by
adding MgCl2 (final concentration 5 mM) and incubating at 37uC.
At 0 min and 15 min the reaction was stopped by mixing with a
solution containing 0.2% (v/v) sodiumdodecylsulfate, 2 mM
EDTA, 2 mM dithiothreitol, 0.5 mM GTP, 0.5 mM GDP and
heating to 65uC. 2 ml aliquots were spotted onto thin-layer plates
(Merck, Darmstadt, Germany) and separated in 1 M KH2PO4
buffer, pH 3.5. The plates were exposed to phosphoscreens
overnight. The screens were imaged on a Typhoon 9400 laser
scanner (GE Healthcare, Freiburg, Germany) and the radiolabeled
spots were quantified using Quantity One software (Bio-Rad,
Munich, Germany).
Statistical analyses
For interaction analyses, GTP binding and competition assays
the intensities of protein bands were analyzed with the
AlphaEaseFC
TM software (Alpha Innotech). After background
correction and normalization with an unspecific band the pixel
intensity of each protein was related to the corresponding control
protein band. Statistics were done using the student’s t-test.
Immunofluorescence
SH-SY5Y cells were differentiated 6 days with 10 mM retinoic
acid [39] and subsequently fixed with 4% paraformaldehyde in
PBS. After 5 min incubation with icecold methanol the cells were
washed twice with PBS and blocked with 10% normal donkey
serum for 30 min. Incubation with primary antibodies was
performed over night at 4uC. After three-times washing with
PBS, 1 h incubation with the labeled Cy2 and Cy3 secondary
antibody at 37uC the cells were mounted with DABCO/Mowiol.
The confocal images were taken with the LSM 510 (Laser
Scanning Microscope, Carl Zeiss MicroImaging GmbH) by using
a pinhole Ø 1,00 Airy Units (corresponding an optical slice
,0,8 mm) without using Z-stacks.
Kinase Assay
For the in vitro kinase assay, N-terminal SF-TAP tagged wild-
type LRRK2 and kinase-dead LRRK2 (K1906M) were purified
via tandem affinity purification as described in [40]. As substrate
MBP-tagged ARHGEF7 purified from E. coli has been used.
Purification of the MBP fusion protein was performed as described
earlier [9]. The in vitro kinase assay using
32P labelled ATP was
performed as described recently [9]. Briefly, SF-TAP tagged
LRRK2 variants bound to anti-FLAG agarose (Sigma) were
incubated with 2 mg of MBP-ARHGEF7 in 30 ml assay buffer
(25 mM Tris-HCl pH 7.5, 5 mM beta-glycerophosphate, 2 mM
DTT, 0.1 mM Na3VO4, 10 mM MgCl2, Cell Signalling)
supplemented with 50 mM MgATP (Cell Signalling) and 3 mCi
Redivue c
32P-ATP (GE-Healthcare). The reaction mix was
incubated for 2 h at 30uC. The reaction was stopped by addition
of 10 ml 5x Laemmli buffer and samples were incubated for two
minutes at 96uC prior to SDS gel-electrophoresis and immuno-
Figure 10. Model of the intermolecular regulation of ARHGEF7 and LRRK2. ARHGEF7 binds as guanine nucleotide exchange factor on
dimeric GDP bound LRRK2. Subsequently the GDP-GTP exchange leads to activation of intrinsic GTPase activity of LRRK2, which induce
autophosphorylation followed by kinase activation of LRRK2. Kinase active LRRK2 recognizes different substrates among them ARHGEF7.
doi:10.1371/journal.pone.0013762.g010
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imager plates to the membranes which were then quantified by a
Typhoon Trio Reader (GE-Healthcare).
Mapping of phosphorylation sites by mass spectrometry
FortheidentificationoftheARHGEF7phosphorylationsites,the
kinase assay was repeated with 100 mM non-labelled ATP. Sample
preparation for mass spectrometry was performed as described
earlier [40]. Briefly, proteins were precipitated by chloroform/
methanol. The protein precipitates were dissolved in 50 mM
ammonium bicarbonate, containing 0.2% RapiGest [41], reduced
with DTT and alkylated with iodoacetamide and proteolysis was
performed by incubation with 2 mg of trypsin (Promega) o/n at
37uC. After proteolysis the RapiGest surfactant was hydrolysed by
adding HCl and incubation for 30 min at RT. Samples were
centrifuged for 10 min (13.0006g, RT) and the supernatants were
transferred to new vials. Sample volumes were reduced to approx.
10 ml in a speed vac. Phosphopeptide enrichment was performed by
TiO2 using protocols published recently [42]. Mass spectrometric
analysis of the samples was performed on an LTQ OrbitrapXL
mass spectrometer (Thermo-Fisher) coupled to an Ultimate 3000
Nano-HPLC (Dionex). In addition to MS/MS, multistage activa-
tion [43] was used for PTM analysis. Database search was
performed against the Uniref 100 database (date: 2009-06-08)
using the Mascot search engine (version: 2.2.06, Matrix Science)
withfollowingparameters:trypsin asenzyme,10ppmasmassrange
for parent ions and 1 Da for fragment ions; carbamidomethyl as
fixed modification and methionine oxidation and serine/threonine
as well as tyrosine phosphorylation as variable modifications.
Supporting Information
Figure S1 Specificity of the LRRK2 antibody. Specificity of the
human-specific anti-LRRK2 antibody, used for immunofluores-
cence analysis, is shown by RNAi mediated knockdown of
LRRK2 (siLRRK2-1) in SH-SY5Y cells in comparison to control
siRNA transfected cells.
Found at: doi:10.1371/journal.pone.0013762.s001 (0.18 MB TIF)
Figure S2 Specificity control for used immunoprecipitation
approach: endogenously expressed LRRK2 shows interaction
with Tubulin but not with the GEF SOS1. Endogenous LRRK2
coupled on ProteinG agarose beads is not able to pull down the
GEF SOS1 from mouse brain lysate, and the coupling of
endogenous SOS1 shows no interaction to endogenous LRRK2
(A). The previously known interaction partner Tubulin Alpha
(TUBA) could be confirmed as endogenous interacting protein of
LRRK2 in mouse brain lysate (B).
Found at: doi:10.1371/journal.pone.0013762.s002 (0.60 MB TIF)
Figure S3 Quantification of the LRRK2 Interaction (WT and
mutations) with ARHGEF7. Pixel densities of three independent
experiments of interaction analyses between LRRK2 with
mutations and ARHGEF7 (Figure 4) were calculated in relation
to interaction between LRRK2 (45) and ARHGEF7.
Found at: doi:10.1371/journal.pone.0013762.s003 (0.16 MB TIF)
Figure S4 Quantification of LRRK2 binding to GTP influenced
by ARHGEF7. Pixel densities of three independent experiments of
GTP-binding of mutated or WT LRRK2 in presence of
ARHGEF7 (Figure 5) were calculated in relation to the GTP-
binding of mutated or WT LRRK2 in presence of empty V5-
vector.
Found at: doi:10.1371/journal.pone.0013762.s004 (0.17 MB TIF)
Figure S5 Pedigree of a family with Parkinson’s disease. The
new potentially pathogenic mutation N1437S is segregating with
disease.
Found at: doi:10.1371/journal.pone.0013762.s005 (0.10 MB TIF)
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